
Eton Pharmaceuticals rose 270.1% from $17.20 to $63.65, ahead of the S&P 500's +10.6%. Its worst day was Sep 30 (−13.0%), and its low came Feb 5 at $14.35.
Nov 18, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Eton Pharmaceuticals closed at its lowest level of the year, 16.6% below where the year started.
−2.7% · S&P 500 −1.2%
EPS of $0.19 beat the $0.17 estimate on $21.3M revenue (est. $20.5M); FY revenue guidance of $110.0M against the $104.7M consensus.
Story events cover the past 12 months · Times ET
+7.5% · S&P 500 −1.4%
Eton Pharmaceuticals shares rose 19.8%, while the S&P 500 rose 0.3%.
+19.8% · S&P 500 +0.3%
EPS of $0.14 beat the $0.13 estimate on $24.3M revenue (est. $22.4M); FY revenue guidance of $120.0M against the $113.0M consensus.
+1.0% · S&P 500 −1.2%
Eton Pharmaceuticals shares rose 13.8%, while the S&P 500 fell 1.0%.
+13.8% · S&P 500 −1.0%
EPS of $0.43 beat the $0.18 estimate on $37.6M revenue (est. $27.1M); FY revenue guidance of $145.0M against the $121.1M consensus.
+44.3%, the year's best day, on 2M shares, the year's heaviest volume · S&P 500 −0.2%
Eton Pharmaceuticals shares fell 13.0%, while the S&P 500 fell 0.2%.
−13.0%, the year's worst day · S&P 500 −0.2%
EPS of $0.50 beat the $0.36 estimate on $57.9M revenue (est. $42.2M); FY revenue guidance of $175.0M against the $149.6M consensus.
+19.7% · S&P 500 +0.3%
Where it ended: a close of $63.65 on Nov 17, 2026. Up next: Q4 2026 earnings on Mar 18, 2027 (EPS est. $0.62, revenue est. $60.1M).
Nothing in the past 12 months.
All ETON dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ETON and SPY from Benzinga historical bars. Not investment advice.